CERN Cerner Corporation

Cerner Declares First Quarterly Dividend

Cerner Declares First Quarterly Dividend

KANSAS CITY, Mo., May 30, 2019 (GLOBE NEWSWIRE) -- Cerner (NASDAQ: CERN) announced its Board of Directors has declared a cash dividend to stockholders of $0.18 per issued and outstanding share. This reflects a $0.03, or 20%, increase compared to the $0.15 preliminary estimate provided on February 5, 2019, when the Company announced its intent to initiate a dividend. The cash dividend will be payable on July 26, 2019, to shareholders of record as of the close of business on June 18, 2019.

“The Board's decision to initiate a quarterly dividend represents a significant milestone for Cerner and reflects our confidence in the stability of our business and long-term growth prospects,” said Marc G. Naughton, chief financial officer of Cerner. “This dividend and our recently expanded share repurchase authorization reflect Cerner’s increased commitment to enhance shareholder value and return capital to shareholders.”

Cerner intends to pay regular quarterly cash dividends, with future declarations subject to approval by its Board of Directors and their determination that the declaration of dividends remains in the best interests of Cerner and its shareholders. The decision of whether to pay future dividends and the amount of any such dividends will be based on the Company’s financial position, results of operations, cash flows, capital requirements, the requirements of applicable law and any other factors the Board of Directors may deem relevant.

About Cerner

Cerner’s health technologies connect people and information systems at more than 27,500 contracted provider facilities worldwide dedicated to creating smarter and better care for individuals and communities. Recognized globally for innovation, Cerner assists clinicians in making care decisions and assists organizations in managing the health of their populations. The company also offers an integrated clinical and financial system to help manage day-to-day revenue functions, as well as a wide range of services to support clinical, financial and operational needs, focused on people. For more information, visit ,  or connect on , , ,  or . Nasdaq: CERN. Smarter Care. Better Outcomes. Healthier You.

All statements in this press release that do not directly and exclusively relate to historical facts constitute forward-looking statements.  These forward-looking statements are based on the current beliefs, expectations and assumptions of Cerner's management with respect to future events and are subject to a number of significant risks and uncertainties.  It is important to note that Cerner's performance, and actual results, financial condition or business could differ materially from those expressed in such forward-looking statements. The words “intends,” “future”, “estimate”, “anticipate”, or the negative of these words, variations thereof or similar expressions are intended to identify such forward-looking statements. For example, our forward-looking statements include statements regarding future dividends. Factors that could cause or contribute to such differences include, but are not limited to: possibility of significant costs and reputational harm related to product related liabilities; potential claims for system errors and warranties; the possibility of interruption at our data centers or client support facilities, or those of third parties with whom we have contracted (such as public cloud providers), that could expose us to significant costs and reputational harm; the possibility of increased expenses, exposure to legal claims and regulatory actions and reputational harm associated with a cyberattack or other breach in our IT security or the IT security of third parties on which we rely; our proprietary technology may be subject to claims for infringement or misappropriation of intellectual property rights of others, or may be infringed or misappropriated by others; potential claims or other risks associated with relying on open source software in our proprietary software solutions or technology-enabled services; material adverse resolution of legal proceedings or other claims; risks associated with our global operations, including without limitation greater difficulty in collecting accounts receivable; risks associated with fluctuations in foreign currency exchange rates; changes in tax laws, regulations or guidance that could adversely affect our tax position and/or challenges to our tax positions in the U.S. and non-U.S. countries; the uncertainty surrounding the impact of the United Kingdom’s vote to leave the European Union (commonly referred to as Brexit) on our global business; risks associated with the unexpected loss or recruitment and retention of key personnel or the failure to successfully develop and execute succession planning to assure transitions of key associates and their knowledge, relationships and expertise; risks associated with failure to timely or effectively manage publicity related to harassment or discrimination claims and legal proceedings if such claims are raised against key personnel; risks related to our dependence on strategic relationships and third-party suppliers; risks inherent with business acquisitions and combinations and the integration thereof into our business or relating to disputes involving such acquisitions or combinations; risks associated with volatility and disruption resulting from global economic or market conditions; significant competition and our ability to quickly respond to market changes, changing technologies and evolving pricing and deployment methods and to bring competitive new solutions, devices, features and services to market in a timely fashion; managing growth in the new markets in which we offer solutions, health care devices or services; long sales cycles for our solutions and services; risks inherent in contracting with government clients, including without limitation, complying with strict compliance and disclosure obligations, navigating complex procurement rules and processes and defending against bid protests; risks associated with our outstanding and future indebtedness, such as compliance with restrictive covenants, which may limit our flexibility to operate our business; changes in accounting standards issued by the Financial Accounting Standards Board or other standard-setting bodies may adversely affect our financial statements; the potential for losses resulting from asset impairment charges; changing political, economic, regulatory and judicial influences, which could impact the purchasing practices and operations of our clients and increase costs to deliver compliant solutions and services; non-compliance with laws, government regulation or certain industry initiatives or failure to deliver solutions or services that enable our clients to comply with laws or regulations applicable to their businesses; variations in our quarterly operating results; potential variations in our sales forecasts compared to actual sales; volatility in the trading price of our common stock and the timing and volume of market activity; inability to reduce expenses and costs to the extent currently anticipated; risks that Cerner’s revenue growth may be lower than anticipated and/or that the mix of revenue shifts to low margin revenue; risks that our stock repurchase program or quarterly dividend program will not be fully implemented or enhance long-term shareholder value; risks that Cerner’s business may be negatively affected as a result of future proxy fights or the actions of activist shareholders; and our directors’ authority to issue preferred stock and the anti-takeover provisions in our corporate governance documents. Additional discussion of these and other risks, uncertainties and factors affecting Cerner’s business is contained in Cerner’s filings with the Securities and Exchange Commission. The reader should not place undue reliance on forward-looking statements, since the statements speak only as of the date that they are made. Except as required by law, Cerner undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events, or changes in our business, results of operations or financial condition over time.

Investor Contact:  Allan Kells, (816) 201-2445,

Media Contact:  Misti Preston, (816) 299-2037,  

Cerner’s Internet Home Page: 

EN
30/05/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cerner Corporation

CERNER sees an upgrade to Slightly Positive due to a better fundamenta...

The general evaluation of CERNER (US), a company active in the Software industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date December 14, 2021, the closing price was USD 77.26 and...

 PRESS RELEASE

Cerner Announces Increased Quarterly Dividend

Cerner Announces Increased Quarterly Dividend Dividend of $0.27 per issued and outstanding share reflects 23% increase KANSAS CITY, Mo., Dec. 10, 2021 (GLOBE NEWSWIRE) --  (NASDAQ: CERN), a global healthcare technology company, today announced that its board of directors declared a cash dividend to stockholders of $0.27 per issued and outstanding share, up 23 percent from the prior quarterly dividend of $0.22. The cash dividend will be payable January 11, 2022, to shareholders of record as of the close of business December 27, 2021. Cerner intends to pay regular quarterly cash dividend...

 PRESS RELEASE

Cerner Names Nasim Afsar, MD MBA as Company’s First Chief Health Offic...

Cerner Names Nasim Afsar, MD MBA as Company’s First Chief Health Officer Experienced Clinical Executive to Lead Patient and Caregiver Experiences KANSAS CITY, Mo., Nov. 16, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CERN), a global healthcare technology company, today announced Nasim Afsar, MD, MBA, MHM, as the company’s first Chief Health Officer, effective January 2022. In this new role, Dr. Afsar will lead Cerner’s more than 1,000 healthcare professionals who provide insight and guidance to product development and improving the lives of patients and caregivers. She will also lead the quality...

 PRESS RELEASE

Cerner Reports Third Quarter 2021 Results

Cerner Reports Third Quarter 2021 Results Delivers Strong Results Across Key MetricsGAAP Operating Margin and Diluted EPS Lower; Adjusted Operating Margin and Adjusted Diluted EPS Both up Sharply vs. Year-Ago QuarterFull-Year Guidance Increased KANSAS CITY, Mo., Oct. 29, 2021 (GLOBE NEWSWIRE) -- (Nasdaq: CERN) today announced results for the 2021 third quarter that ended September 30, 2021. The third quarter 2021 earnings release can be viewed as well as on the company’s website at . Cerner will host an earnings conference call to provide additional detail on the Company’s results a...

 PRESS RELEASE

Cerner Enviza Aims To Accelerate Therapies And Improve Patient Outcome...

Cerner Enviza Aims To Accelerate Therapies And Improve Patient Outcomes Combining decades of healthcare, life sciences and collaborative research to transform the way care is delivered KANSAS CITY, Mo., Oct. 26, 2021 (GLOBE NEWSWIRE) -- (NASDAQ: CERN), a global healthcare technology company, announces the launch of a new operating unit, SM, that offers data-driven solutions and research services to help bring clarity to multi-dimensional data through real-world evidence and insights. The combined expertise of the Cerner and Kantar Health teams is expected to help accelerate discovery, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch